Hirashima Yuka | Pharmacy Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
スポンサーリンク
概要
- Hirashima Yukaの詳細を見る
- 同名の論文著者
- Pharmacy Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japanの論文著者
関連著者
-
Kobayashi Takeshi
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
-
Sakamaki Hisashi
Hematology Division Tokyo Metropolitan Cancer And Infectious Diseases Center Komagome Hospital
-
Ohashi Kazuteru
Hematology Division Tokyo Metropolitan Cancer And Infectious Diseases Center Komagome Hospital
-
Kakihana Kazuhiko
Hematology Division Tokyo Metropolitan Cancer And Infectious Diseases Center Komagome Hospital
-
Hirashima Yuka
Pharmacy Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
-
Ando Minoru
Nephrology Division Tokyo Metropolitan Cancer And Infectious Diseases Center Komagome Hospital
-
Akiyama Hideki
Hematology Division Tokyo Metropolitan Cancer And Infectious Diseases Center Komagome Hospital
-
Yamamoto Masahide
Hematology Division Tokyo Metropolitan Cancer And Infectious Diseases Center Komagome Hospital
-
Yamaguchi Takuhiro
Division Of Biostatistics Tohoku University Graduate School Of Medicine
-
Sakamaki Hisashi
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
-
Ohashi Kazuteru
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
-
Mori Jinichi
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
-
Akiyama Hideki
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
-
Yamamoto Masahide
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
著作論文
- Risk Assessment for Acute Kidney Injury after Allogeneic Hematopoietic Stem Cell Transplantation Based on Acute Kidney Injury Network Criteria
- Poor Outcome of Myeloablative Conditioned Allogeneic Bone Marrow Transplantation for Myelofibrosis